Bayer’s Asundexian FXIa Inhibitor Demonstrates Reduction in Ischemic Stroke in OCEANIC-STROKE Study

April 17, 2026—The results from the OCEANIC-STROKE study were published by Mukul Sharma, MD, et al in The New England Journal of Medicine (NEJM; 2026;394:1467-1479).

Stereotaxis to Acquire Robocath

April 15, 2026–Stereotaxis, a St. Louis, Missouri–based company focused on robotics for endovascular intervention, announced that it has entered into a definitive agreement to acquire Robocath.

Penumbra’s CAVT Evaluated in 90-Day STORM-PE Data

April 13, 2026—Penumbra, Inc. announced 90-day results of the STORM-PE randomized controlled trial (RCT) that is evaluating computer-assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash device plus anticoagulation versus anticoagulation alone for the treatment of patients with acute intermediate-high risk pulmonary embolism (PE).

PROTECT H2H Directly Compares Stroke Protection Devices During TAVR 

April 12, 2026—The American College of Cardiology (ACC) announced that findings from the PROTECT H2H randomized trial were presented at the ACC.26 annual scientific session.

Innoventric’s Unica System to Treat Severe TR Granted FDA Breakthrough Device Designation

April 10, 2026—Innoventric, an Israel-based medical device company, announced that its Unica system for the treatment of severe tricuspid regurgitation (TR) has been granted FDA Breakthrough Device designation.

Mermaid’s Angel Catheter Approved in Europe for Pulmonary Embolism Prevention

April 10, 2026—Mermaid Medical Group announced that the company’s Angel catheter has received European CE Mark approval for the prevention of pulmonary embolism.

FDA Approves TRICURE US Pivotal Trial of TriCares’ Topaz TTVR System

April 9, 2026—TriCares SAS announced it has received investigational device exemption (IDE) approval from the FDA to conduct a pivotal clinical trial for its Topaz transcatheter tricuspid valve replacement (TTVR) system.

STAR Trial of TAVR With MiRus’ Siegel THV Begins Enrollment

April 9, 2026—MiRus, LLC, announced commencement of enrollment and the treatment of the first patients in the STAR trial of transcatheter aortic valve replacement with the company’s Siegel 8-F transcatheter heart valve (THV).